发布求助
文献互助 智能选刊 最新文献

Expert Review of Precision Medicine and Drug Development最新文献

筛选
英文 中文
Precision Medicine Paradigms in Allergic Rhinitis: Navigating Immunotherapy and Digital Healthcare 过敏性鼻炎的精准医疗范例：免疫疗法与数字医疗的导航
IF 1
Expert Review of Precision Medicine and Drug Development Pub Date : 2024-07-08 DOI: 10.1080/23808993.2024.2373697
Rutuja Vinchurkar, Sanika Kole, Rutuja Desai, Prajakta Wagh, A. Gawade, A. Kuchekar
{"title":"Precision Medicine Paradigms in Allergic Rhinitis: Navigating Immunotherapy and Digital Healthcare","authors":"Rutuja Vinchurkar, Sanika Kole, Rutuja Desai, Prajakta Wagh, A. Gawade, A. Kuchekar","doi":"10.1080/23808993.2024.2373697","DOIUrl":"https://doi.org/10.1080/23808993.2024.2373697","url":null,"abstract":"","PeriodicalId":12124,"journal":{"name":"Expert Review of Precision Medicine and Drug Development","volume":null,"pages":null},"PeriodicalIF":1.0,"publicationDate":"2024-07-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141668534","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Advanced laboratory techniques in diffuse large B-cell lymphoma treated with CAR-T: the role for pathologists CAR-T 治疗弥漫大 B 细胞淋巴瘤的先进实验室技术：病理学家的作用
IF 1.2
Expert Review of Precision Medicine and Drug Development Pub Date : 2024-04-11 DOI: 10.1080/23808993.2024.2342261
Phillip D. Michaels
{"title":"Advanced laboratory techniques in diffuse large B-cell lymphoma treated with CAR-T: the role for pathologists","authors":"Phillip D. Michaels","doi":"10.1080/23808993.2024.2342261","DOIUrl":"https://doi.org/10.1080/23808993.2024.2342261","url":null,"abstract":"","PeriodicalId":12124,"journal":{"name":"Expert Review of Precision Medicine and Drug Development","volume":null,"pages":null},"PeriodicalIF":1.2,"publicationDate":"2024-04-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140715213","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Tumor growth rate to assess therapy response to immune-based combinations for metastatic renal cell carcinoma 用肿瘤生长率评估转移性肾细胞癌免疫复合物的治疗反应
IF 1.2
Expert Review of Precision Medicine and Drug Development Pub Date : 2024-03-18 DOI: 10.1080/23808993.2024.2330422
V. Mollica, M. Rosellini, Stefano Brocchi, Francesco Galuppi, A. Paccapelo, Valentina Tateo, Andrea Marchetti, Elisa Tassinari, Francesco Mantuano, M. Santoni, F. Massari
{"title":"Tumor growth rate to assess therapy response to immune-based combinations for metastatic renal cell carcinoma","authors":"V. Mollica, M. Rosellini, Stefano Brocchi, Francesco Galuppi, A. Paccapelo, Valentina Tateo, Andrea Marchetti, Elisa Tassinari, Francesco Mantuano, M. Santoni, F. Massari","doi":"10.1080/23808993.2024.2330422","DOIUrl":"https://doi.org/10.1080/23808993.2024.2330422","url":null,"abstract":"","PeriodicalId":12124,"journal":{"name":"Expert Review of Precision Medicine and Drug Development","volume":null,"pages":null},"PeriodicalIF":1.2,"publicationDate":"2024-03-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140233416","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Advances in the field of developing biomarkers for re-irradiation: a how-to guide to small, powerful data sets and artificial intelligence 再照射生物标志物开发领域的进展：小型、强大数据集和人工智能操作指南
IF 1.2
Expert Review of Precision Medicine and Drug Development Pub Date : 2024-03-11 DOI: 10.1080/23808993.2024.2325936
Chaudhry Huma, Lee Hawon, Jagasia Sarisha, Tasci Erdal, Camphausen Kevin, Krauze Andra Valentina
{"title":"Advances in the field of developing biomarkers for re-irradiation: a how-to guide to small, powerful data sets and artificial intelligence","authors":"Chaudhry Huma, Lee Hawon, Jagasia Sarisha, Tasci Erdal, Camphausen Kevin, Krauze Andra Valentina","doi":"10.1080/23808993.2024.2325936","DOIUrl":"https://doi.org/10.1080/23808993.2024.2325936","url":null,"abstract":"","PeriodicalId":12124,"journal":{"name":"Expert Review of Precision Medicine and Drug Development","volume":null,"pages":null},"PeriodicalIF":1.2,"publicationDate":"2024-03-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140253399","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Shorting vorasidenib for IDH mutant low-grade glioma 缩短vorasidenib治疗IDH突变低级别胶质瘤的疗程
IF 1.2
Expert Review of Precision Medicine and Drug Development Pub Date : 2024-02-12 DOI: 10.1080/23808993.2024.2316347
Eric T Wong
{"title":"Shorting vorasidenib for IDH mutant low-grade glioma","authors":"Eric T Wong","doi":"10.1080/23808993.2024.2316347","DOIUrl":"https://doi.org/10.1080/23808993.2024.2316347","url":null,"abstract":"","PeriodicalId":12124,"journal":{"name":"Expert Review of Precision Medicine and Drug Development","volume":null,"pages":null},"PeriodicalIF":1.2,"publicationDate":"2024-02-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139844323","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Shorting vorasidenib for IDH mutant low-grade glioma 缩短vorasidenib治疗IDH突变低级别胶质瘤的疗程
IF 1.2
Expert Review of Precision Medicine and Drug Development Pub Date : 2024-02-12 DOI: 10.1080/23808993.2024.2316347
Eric T Wong
{"title":"Shorting vorasidenib for IDH mutant low-grade glioma","authors":"Eric T Wong","doi":"10.1080/23808993.2024.2316347","DOIUrl":"https://doi.org/10.1080/23808993.2024.2316347","url":null,"abstract":"","PeriodicalId":12124,"journal":{"name":"Expert Review of Precision Medicine and Drug Development","volume":null,"pages":null},"PeriodicalIF":1.2,"publicationDate":"2024-02-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139784440","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The future of precision medicine in oncology 肿瘤精准医疗的未来
IF 1.2
Expert Review of Precision Medicine and Drug Development Pub Date : 2023-12-08 DOI: 10.1080/23808993.2023.2292988
Ahmad Z. Al Meslamani
{"title":"The future of precision medicine in oncology","authors":"Ahmad Z. Al Meslamani","doi":"10.1080/23808993.2023.2292988","DOIUrl":"https://doi.org/10.1080/23808993.2023.2292988","url":null,"abstract":"","PeriodicalId":12124,"journal":{"name":"Expert Review of Precision Medicine and Drug Development","volume":null,"pages":null},"PeriodicalIF":1.2,"publicationDate":"2023-12-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138586975","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Peptide receptor radionuclide therapy in neuroendocrine neoplasms and related tumors: from fundamentals to personalization and the newer experimental approaches 神经内分泌肿瘤及相关肿瘤的肽受体放射性核素治疗:从基础到个性化和新的实验方法
IF 1.2
Expert Review of Precision Medicine and Drug Development Pub Date : 2023-05-17 DOI: 10.1080/23808993.2023.2211090
Sarvesh Loharkar, S. Basu
{"title":"Peptide receptor radionuclide therapy in neuroendocrine neoplasms and related tumors: from fundamentals to personalization and the newer experimental approaches","authors":"Sarvesh Loharkar, S. Basu","doi":"10.1080/23808993.2023.2211090","DOIUrl":"https://doi.org/10.1080/23808993.2023.2211090","url":null,"abstract":"","PeriodicalId":12124,"journal":{"name":"Expert Review of Precision Medicine and Drug Development","volume":null,"pages":null},"PeriodicalIF":1.2,"publicationDate":"2023-05-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48352759","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Identifying patients suitable for targeted adjuvant therapy: advances in the field of developing biomarkers for tumor recurrence following irradiation. 确定适合靶向辅助治疗的患者:放射治疗后肿瘤复发生物标志物的研究进展。
IF 1.2
Expert Review of Precision Medicine and Drug Development Pub Date : 2023-01-01 Epub Date: 2023-11-16 DOI: 10.1080/23808993.2023.2276927
S Jagasia, E Tasci, Ying Zhuge, K Camphausen, A V Krauze
{"title":"Identifying patients suitable for targeted adjuvant therapy: advances in the field of developing biomarkers for tumor recurrence following irradiation.","authors":"S Jagasia, E Tasci, Ying Zhuge, K Camphausen, A V Krauze","doi":"10.1080/23808993.2023.2276927","DOIUrl":"10.1080/23808993.2023.2276927","url":null,"abstract":"<p><strong>Introduction: </strong>Radiation therapy (RT) is commonly used to treat cancer in conjunction with chemotherapy, immunotherapy, and targeted therapies. Despite the effectiveness of RT, tumor recurrence due to treatment resistance still lead to treatment failure. RT-specific biomarkers are currently lacking and remain challenging to investigate with existing data since, for many common malignancies, standard of care (SOC) paradigms involve the administration of RT in conjunction with other agents.</p><p><strong>Areas covered: </strong>Established clinically relevant biomarkers are used in surveillance, as prognostic indicators, and sometimes for treatment planning; however, the inability to intercept early recurrence or predict upfront resistance to treatment remains a significant challenge that limits the selection of patients for adjuvant therapy. We discuss attempts at intercepting early failure. We examine biomarkers that have made it into the clinic where they are used for treatment monitoring and management alteration, and novel biomarkers that lead the field with targeted adjuvant therapy seeking to harness these.</p><p><strong>Expert opinion: </strong>Given the growth of data correlating interventions with omic analysis toward identifying biomarkers of radiation resistance, more robust markers of recurrence that link to biology will increasingly be leveraged toward targeted adjuvant therapy to make a successful transition to the clinic in the coming years.</p>","PeriodicalId":12124,"journal":{"name":"Expert Review of Precision Medicine and Drug Development","volume":null,"pages":null},"PeriodicalIF":1.2,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10655913/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138046631","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Identification of drug combinations for lung cancer patients whose tumors are unresponsive to targeted therapy: clinical bases and future directions 肿瘤对靶向治疗无反应的肺癌患者联合用药的鉴定:临床基础和未来方向
IF 1.2
Expert Review of Precision Medicine and Drug Development Pub Date : 2022-01-02 DOI: 10.1080/23808993.2022.2050369
D. Rocco, L. Della Gravara, P. Maione, G. Palazzolo, C. Gridelli
{"title":"Identification of drug combinations for lung cancer patients whose tumors are unresponsive to targeted therapy: clinical bases and future directions","authors":"D. Rocco, L. Della Gravara, P. Maione, G. Palazzolo, C. Gridelli","doi":"10.1080/23808993.2022.2050369","DOIUrl":"https://doi.org/10.1080/23808993.2022.2050369","url":null,"abstract":"ABSTRACT Introduction Targeted therapies have granted unprecedented results in terms of survival and safety to oncogene-addicted advanced NSCLC patients. However, these patients eventually become unresponsive to such treatments due to several different resistance mechanisms. Moreover, the current lack of subsequent-line treatments forces these patients to receive less tolerable and less effective chemotherapy regimens. Areas covered Thus, this paper aims to review the current state of the art with respect to targeted therapies for the treatment of oncogene-addicted advanced NSCLC patients, focusing on resistance mechanisms and on drug combinations to overcome them. Expert opinion We strongly believe that a personalized sequential treatment approach based on resistance mutations will become the standard of care for oncogene-addicted advance NSCLC patients. Furthermore, we believe that TKI combination regimens will play a key role. In the same vein, ICI-containing regimens will play a part both in patients without druggable resistance mutations and in patients progressing on TKI therapies.","PeriodicalId":12124,"journal":{"name":"Expert Review of Precision Medicine and Drug Development","volume":null,"pages":null},"PeriodicalIF":1.2,"publicationDate":"2022-01-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"60122089","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信